Hyloris Pharmaceuticals SA 2023 AR2
The report highlights Hyloris' progress in 2023, including the U.S. FDA approvals and launches of Maxigesic IV and Podofilox gel. The company expanded its pipeline to 19 portfolio products, with 16 in development, focusing on addressing unmet medical needs through the 505(b)(2) regulatory pathway. In sustainability, Hyloris aligned its ESG strategy with the UN Sustainable Development Goals, focusing on good health, environmental sustainability, and responsible leadership. The company also reported a strong financial position with 30.4 million euros in cash and zero financial debt, while preparing for a double materiality assessment in 2024.
Company: Hyloris Pharmaceuticals SA
Sector: Manufacturing
Country: Belgium
Year: 2023
Type: AR2
Pages: 160
Back to company
Hyloris Pharmaceuticals SA
Annual Report
The report highlights Hyloris' progress in 2023, including the U.S. FDA approvals and launches of Maxigesic IV and Podofilox gel. The company expanded its pipeline to 19 portfolio products, with 16 in development, focusing on addressing unmet medical needs through the 505(b)(2) regulatory pathway. In sustainability, Hyloris aligned its ESG strategy with the UN Sustainable Development Goals, focusing on good health, environmental sustainability, and responsible leadership. The company also reported a strong financial position with 30.4 million euros in cash and zero financial debt, while preparing for a double materiality assessment in 2024.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees